Overview Dividends

(TNGX) Tango Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US87583X1090

PRMT5 Inhibitors, Brain-Penetrant Agent, Immune Evasion Reverser

Biotechnology
Market Cap in USD: 1,193m
IPO / Inception: 2020-09-03
Return 12m vs S&P 500: 170%

EPS (Earnings per Share)

EPS (Earnings per Share) of TNGX over the last years for every Quarter: "2020-12": -0.0033, "2021-03": -0.01, "2021-06": -0.16, "2021-09": -0.28, "2021-12": -0.25, "2022-03": -0.29, "2022-06": -0.28, "2022-09": -0.33, "2022-12": -0.33, "2023-03": -0.32, "2023-06": -0.23, "2023-09": -0.23, "2023-12": -0.32, "2024-03": -0.35, "2024-06": -0.24, "2024-09": -0.27, "2024-12": -0.34, "2025-03": -0.36, "2025-06": -0.35, "2025-09": -0.14, "2025-12": 0,
EPS CAGR: 43.61%
EPS Trend: 39.8%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of TNGX over the last years for every Quarter: 2020-12: 9.141, 2021-03: 6.386, 2021-06: 18.153, 2021-09: 6.787, 2021-12: 5.716, 2022-03: 5.758, 2022-06: 5.771, 2022-09: 6.92, 2022-12: 6.411, 2023-03: 5.766, 2023-06: 14.598, 2023-09: 10.732, 2023-12: 5.431, 2024-03: 6.471, 2024-06: 19.875, 2024-09: 11.607, 2024-12: 4.117, 2025-03: 5.392, 2025-06: 3.181, 2025-09: 53.811, 2025-12: null,
Rev. CAGR: 81.83%
Rev. Trend: 16.2%
Last SUE: 2.32
Qual. Beats: 1

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 91.3%
Value at Risk 5%th 136%
Relative Tail Risk -9.58%
Reward TTM
Sharpe Ratio 1.50
Alpha 178.05
CAGR/Max DD 0.09
Character TTM
Hurst Exponent 0.589
Beta 1.720
Beta Downside 1.282
Drawdowns 3y
Max DD 91.46%
Mean DD 43.97%
Median DD 42.31%

Description: TNGX Tango Therapeutics December 26, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a Boston-based precision-oncology biotech that targets methylthioadenosine-cooperative PRMT5 pathways. Its lead assets include TNG462 (a PRMT5 inhibitor in a combined Phase 1/2 trial for pancreatic and non-small-cell lung cancer) and TNG456, a brain-penetrant PRMT5 inhibitor being evaluated for glioblastoma, as well as TNG260, a repressor-element-1 silencing transcription inhibitor aimed at reversing immune evasion in LKB1-deficient lung tumors.

As of the latest 10-Q, Tango reported approximately $115 million in cash and marketable securities, giving it runway through Q4 2025 at its current burn rate of roughly $30 million per quarter. The PRMT5 inhibitor class has attracted $2.5 billion of cumulative R&D spend in 2023, reflecting strong investor interest in epigenetic targets, while the broader biotech sector is benefiting from a 12 % YoY increase in venture funding for early-stage oncology programs.

For a deeper, data-driven view of Tango’s valuation metrics and comparable peers, you might explore the analysis tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-100.5m TTM) > 0 and > 6% of Revenue (6% = 3.99m TTM)
FCFTA -0.70 (>2.0%) and ΔFCFTA -34.89pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 218.5% (prev 606.7%; Δ -388.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.69 (>3.0%) and CFO -145.8m <= Net Income -100.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (111.0m) change vs 12m ago 2.27% (target <= -2.0% for YES)
Gross Margin 97.29% (prev 95.68%; Δ 1.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 23.64% (prev 12.31%; Δ 11.33pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -17.80 (EBITDA TTM -104.0m / Interest Expense TTM -5.98m) >= 6 (WARN >= 3)

Altman Z'' -18.58

(A) 0.69 = (Total Current Assets 163.8m - Total Current Liabilities 18.4m) / Total Assets 210.1m
(B) -2.69 = Retained Earnings (Balance) -564.4m / Total Assets 210.1m
warn (B) unusual magnitude: -2.69 — check mapping/units
(C) -0.38 = EBIT TTM -106.4m / Avg Total Assets 281.3m
(D) -11.26 = Book Value of Equity -564.2m / Total Liabilities 50.1m
Total Rating: -18.58 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.15

1. Piotroski 1.0pt
2. FCF Yield -13.65%
3. FCF Margin data missing
4. Debt/Equity 0.22
5. Debt/Ebitda 0.23
6. ROIC - WACC (= -76.44)%
7. RoE -60.80%
8. Rev. Trend 16.25%
9. EPS Trend 39.85%

What is the price of TNGX shares?

As of January 07, 2026, the stock is trading at USD 9.67 with a total of 1,776,870 shares traded.
Over the past week, the price has changed by +12.05%, over one month by +0.73%, over three months by +27.57% and over the past year by +217.05%.

Is TNGX a buy, sell or hold?

Tango Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy TNGX.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the TNGX price?

Issuer Target Up/Down from current
Wallstreet Target Price 13.3 37%
Analysts Target Price 13.3 37%
ValueRay Target Price 11.2 15.3%

TNGX Fundamental Data Overview January 03, 2026

Market Cap USD = 1.19b (1.19b USD * 1.0 USD.USD)
P/S = 17.9432
P/B = 7.4563
Beta = 1.724
Revenue TTM = 66.5m USD
EBIT TTM = -106.4m USD
EBITDA TTM = -104.0m USD
Long Term Debt = 34.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.10m USD (from shortTermDebt, last quarter)
Debt = 34.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -23.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.08b USD (1.19b + Debt 34.8m - CCE 152.8m)
Interest Coverage Ratio = -17.80 (Ebit TTM -106.4m / Interest Expense TTM -5.98m)
FCF Yield = -13.65% (FCF TTM -146.8m / Enterprise Value 1.08b)
FCF Margin = -220.7% (FCF TTM -146.8m / Revenue TTM 66.5m)
Net Margin = -151.1% (Net Income TTM -100.5m / Revenue TTM 66.5m)
Gross Margin = 97.29% ((Revenue TTM 66.5m - Cost of Revenue TTM 1.80m) / Revenue TTM)
Gross Margin QoQ = 98.97% (prev 80.35%)
Tobins Q-Ratio = 5.12 (Enterprise Value 1.08b / Total Assets 210.1m)
Interest Expense / Debt = 1.67% (Interest Expense 581.0k / Debt 34.8m)
Taxrate = -0.06% (negative due to tax credits) (-10.0k / 15.9m)
NOPAT = -106.5m (EBIT -106.4m * (1 - -0.06%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 8.88 (Total Current Assets 163.8m / Total Current Liabilities 18.4m)
Debt / Equity = 0.22 (Debt 34.8m / totalStockholderEquity, last quarter 160.0m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -23.6m / EBITDA -104.0m)
Debt / FCF = 0.16 (negative FCF - burning cash) (Net Debt -23.6m / FCF TTM -146.8m)
Total Stockholder Equity = 165.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.83% (Net Income -100.5m / Total Assets 210.1m)
RoE = -60.80% (Net Income TTM -100.5m / Total Stockholder Equity 165.3m)
RoCE = -53.17% (EBIT -106.4m / Capital Employed (Equity 165.3m + L.T.Debt 34.8m))
RoIC = -64.39% (negative operating profit) (NOPAT -106.5m / Invested Capital 165.3m)
WACC = 12.05% (E(1.19b)/V(1.23b) * Re(12.35%) + D(34.8m)/V(1.23b) * Rd(1.67%) * (1-Tc(-0.00)))
Discount Rate = 12.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 7.62%
Fair Price DCF = unknown (Cash Flow -146.8m)
EPS Correlation: 39.85 | EPS CAGR: 43.61% | SUE: 4.0 | # QB: 1
Revenue Correlation: 16.25 | Revenue CAGR: 81.83% | SUE: 2.32 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.30 | Chg30d=+0.010 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.29 | Chg30d=+0.017 | Revisions Net=+5 | Growth EPS=-44.0% | Growth Revenue=-88.1%

Additional Sources for TNGX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle